ASP 4070
Alternative Names: ASP JRCv2.0; ASP-4070; CryJ2 -DNA-LAMP; CryJ2 DNA LAMP plasmid vaccine; CryJ2-DNA-lysosomal associated membrane protein plasmid; Japanese red cedar LAMP vaccine; Japanese red cedar pollen allergy immunotherapy - Immunomic; JRC LAMP vaccine; JRC LAMP vax vaccine; JRC-LAMP-vax; JRC2-LAMP-vax; Sugi allergy vaccineLatest Information Update: 27 Sep 2021
At a glance
- Originator Immunomic Therapeutics
- Developer Astellas Pharma; Immunomic Therapeutics
- Class DNA vaccines; Japanese cedar pollen allergy immunotherapies; Vaccines
- Mechanism of Action Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic rhinitis; Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-II for Tree pollen hypersensitivity in Japan (Intradermal)
- 27 Oct 2018 Astellas Pharma completes a phase II trial in Tree-pollen hypersensitivity in Japan (NCT03101267)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Tree pollen hypersensitivity in Japan (IM, Injection)